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Abstract. Concentrations and ex vivo production of 
interleukin- (IL-1 /?), tumour necrosis factor-a 
(TNF), interleukin-6 (IL-6), interleukin-1 receptor 
antagonist (IL-1RA) and TNF soluble receptors 
were followed in bronchoalveolar lavage (BAL) 
fluid and blood from 10 HIV -seronegative patients 
with Pneumocystis carinii pneumonia (PCP) and 
compared with values found in healthy volunteers. 
During the acute phase of PCP, TNF but not IL-6 or 
IL-1/? was detectable in BAL fluid. At that time, 
plasma concentrations of the proinfiammatory cyto­
kines were low, whereas plasma concentrations of 
the anti-inflammatory cytokines were high. The ex vivo 
production capacity of proinfiammatory cytokines was 
suppressed in the acute phase, in the blood as well as 
at the site of infection. During convalescence the 
production capacity of the blood cells normalized. 
The I.L-1RA production capacity of the alveolar 
cells was also suppressed in the acute phase, but 
preserved in blood cells.
Keywords. Interleukin-1, interleukin-1 receptor 
antagonist, interleukin-6, Pneumocystis carinii pneumo­
nia, sTNF receptors,TNF-a.
Introduction
Pneumocystis carinii is an intriguing pathogen, mainly 
causing pulmonary infections in immunocompromised 
hosts. Although deficient cellular immunity is consid­
ered a major predisposing factor for the development of 
Pneumocystis carinii pneumonia (PCP), the underlying 
mechanisms are still unclear. Clinical and experimental 
data suggest that CD4'h T-lymphocytes are critical in 
protection against PCP [1-3]. However, CD4+ lympho­
cytes are unlikely to function directly as effector cells in 
killing the organisms. Which cells act as effector cells 
is not clear, although macrophages have been shown 
to interact with the organisms [4-5]. Cytokines, the
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intercellular messengers, mainly derived from 
macrophages or T-helper lymphocyte subsets, are 
involved in many inflammatory processes and are 
likely to be involved in the host defence against 
Pneumocystis carinii (P. carinii), but their exact 
role in PCP is not yet clear.
In vitro studies have shown that P, carinii possesses 
binding sites for tumour necrosis factor-a (TNF) and 
that this cytokine is capable of killing P. carinii [6-8]. 
In mice TNF and interleukin-1 /? (IL-10) are critical in 
the clearance of Pneumocystis, and interleukin-6
♦
(IL-6) regulates pulmonary inflammation and anti­
body response during resolution of PCP [9-11]. In 
addition, several authors have reported the ability of 
Pneumocystis to stimulate in vivo and in vitro produc­
tion of TNF by alveolar macrophages [12-17]. Thus, as 
in many bacterial and protozoal infections, IL-1, IL-6 
and TNF seem to play a role in the pathogenesis of
PCP.
We therefore studied the profile of these cytokines 
and their inhibitors in blood as well as at the site of 
infection in patients with PCP. Although at present 
most PCP episodes are seen in patients with HIV 
infection, it is still an important opportunistic infection 
in other immunocompromised patients, notably organ 
transplant patients and patients with lymphatic 
malignancies.
A series of cases of PCP in such HIV-seronegative 
patients, mainly renal transplant recipients, recently 
diagnosed at our hospital enabled us to follow 
cytokine concentrations and production capacity 
in bronchoalveolar lavage (BAL) fluid and in the 
blood.
Materials and methods
Patients
All HIV-seronegative adult patients with PCP, diag­
nosed by BAL, between October 1992 and March 
1993 were included in the study. Diagnosis of PCP 
was based on demonstration of P. carinii organisms
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Table 1 . Cell differential (median and range) in BAL and peripheral blood
Healthy control subjects
BAL
t
Peripheral blood
Granulocytes (%) Lymphocytes (%) Macrophages (%) Granulocytes (%) Lymphocytes (%) Monocytes (%)
Healthy control subjects 2 3 95 57 35 4
(1-5) ( 1 - 8) (92-99) (18-65) (25-61) (3-6)
PCP patients 7 7 75 82 10 4
{2-45) (1-25) (45-97) (4-99) (1-77) (0-16)
on Churukian-Schenk amoniacal silver-stained and 
Giemsa-stained BAL specimen [18], At the time of 
BAL, blood samples from all patients were taken for 
measurement of circulating and ex  v/vo-produced 
cytokines and inhibitors; another sample was 
obtained after full recovery. Nine patients were 
non-smokers. All patients were proved to be sero­
negative for HIV. None of the patients received non­
steroidal anti-inflammatory drugs or pentoxyfylline.
The study was approved by the hospital ethical 
committee and informed consent was obtained from 
all patients and healthy control subjects,
Control subjects
Eight non-smoking subjects who volunteered to 
undergo BAL were used as controls. They were all 
in good health and none had risk factors for HIV 
infection. HIV testing was not done for ethical 
reasons. None of them used medication or had 
evidence of lung disease or a history of recent 
respiratory tract infections. Before the BAL, a blood 
sample was taken for measurement of cytokines and 
white blood cell count.
Bronchoalveolar lavage
After topical lidocaine anaesthesia of the oropharynx 
and bronchial tree, a flexible fibreoptic bronchoscope 
was introduced into the bronchial tree and, after 
inspection, wedged in a subsegmented bronchus 
serving the area of greatest radiological abnormality. 
In the controls the lavage was done in the right middle 
lobe. Bronchoalveolar-lavage was performed by 
injecting and aspirating 6-8 aliquots of 20 mL of 
sterile saline. The BAL fluid was collected via a 
closed system in a polypropylene flask. In patients 
most of the BAL fluid was used for diagnosis, the 
remaining fluid (in general 10-20 mL) for cytokine 
assessment.
Processing BAL fluid
Immediately after BAL, the flask was put on ice and 
transported to the laboratory. A 30 mL sample was 
taken for a cell count and cell viability was assessed by 
trypan blue dye exclusion. The remaining fluid was 
centrifuged at 500# for 15min. The supernatant was 
removed and 1% bovine serum albumin (BSA; Sigma, 
St Louis, MO, USA) was added. The fluid was then
Table 2. Clinical characteristics of patients with PCP
Patient number 1 2 3 4 5 6 7 8 9 10
Underlying condition Renal Renal N H L Renal Renal Renal Renal Renal Auto-immune Renal
TX TX TX TX TX TX TX disease TX
Duration of symptoms 4 3 < 1 <  1 . < 1 3 1 2 6 1
(weeks)
CMVConcom itant infections PTB S t aphy to c occur — CMV — — 9 —
aureus sepsis
Pao-i (kPa) 5-0 6-5 10*2 8-3 6-0 8-5 8-5 9-4 6-9 8-0
On respirator Yes Yes N o No Yes No No No Yes ' No
Body temperature (°C)
39-6at time of first sample 38*5 37-8 38-3 37-8 39-5 39*2 39-0 40*4 38*0
Prednisone dose (mg)
at time of BAL 80 15 0 80 40 80 80 80 80 80
at recovery or before death 20 10 0 10 50 20 20 10 100 25
Other immuno AZA CsA — AZA CsA CsA CsA CsA — CsA
suppressive drugs AZA AZA AZA
Outcome Cure Cure Cure Cure Death Cure Cure Cure Death Death
Cure\death
3at week 5 7 i i 3 1 2 1 2
TX, Transplantation; N H L, non-Hodgkin lymphoma; PTB, pulmonary tuberculosis; CMV, Cytomegalovirus early antigen detected in BAL 
fluid and therapy with gancyclovir; P ao2, arterial oxygen pressure; AZA, azathioprine; CsA, cyclosporin A.
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Figure 1 . Concentration (median and range, in ngm L  ’ ) of cyto­
kines in BAL fluid (a) and plasma (b) in volunteers and in HIV- 
seroncgative patients with PCP during the acute phase and in 
recovery (for plasma only). Bars =  ranges.
filter sterilized, aliquoted and frozen at -80°C until 
assayed.
The pellet was resuspended in Dulbccco's modified 
Eagle medium (DMEM) at a concentration of 
0-5 x 106 viable macrophages per mL; 100/¿L was 
taken for preparing cytocentrifuged Giemsa-stained 
preparations and half of the remaining fluid was then 
incubated in 4-mL closed polystyrene tubes (Greiner, 
Alphen aan de Rijn, The Netherlands) without any 
addition (unstimulated culture) and the other half was 
incubated with lipoplysaccharide (LPS; Escherichia 
coii serotype 055:B5, Sigma) at a final concentration 
of 10/igmL“' 1. All incubations were performed at 
37°C for 24 h. After incubation the tubes were cen­
trifuged at 1200g for lOmin and the supernatant and 
cell pellets separately frozen at — 80DC until cytokine 
analysis.
Processing whole blood
Venous blood was drawn from patients and volunteers 
for cytokine assessment in whole blood as described 
previously [19]. In brief, venous blood was collected 
aseptically into three 5-mL-draw sterile vacuum tubes, 
containing 7-2 mg of lyophilized EDTA and 250 jiL of 
aprotinin (Trasylol 2500 KIU, Bayer, Leverkussen,
Germany; final concentration 625 KIE mL“1. One 
tube was immediately centrifuged at 1250# for 10 min 
and then plasma was transferred to a polypropylene 
tube (Eppendorf, Sarstedt, Nümbrecht, Germany) and 
centrifuged at 15 000# for 1 min to remove the platelets. 
This platelet-poor plasma was pipetted into another 
sterile polypropylene tube and frozen at -80°C until 
cytokine analysis. In one of the two remaining tubes 
50 juL of LPS was added (final concentration 
10/igmL"1) to stimulate cytokine production. This 
tube and the third tube were then incubated at 30°C 
for 24h. After incubation the tubes were centrifuged 
and the plasma frozen at -80°C as described above.
Cytokine assays
Plasma and BAL samples were analysed by means of 
specific radioimmunoassays for IL-1/?, 11-1 receptor 
antagonist (IL-1RA) and TNF [20,21]. An enzyme- 
linked binding assay (ELIBA; Hoffman la Roche, 
Basel, Switzerland) was used for soluble receptors 
of TNF (sTNF-R; p55, p75) and a bioassay (B9 
hybridoma cell line) for IL-6. The detection limits of the 
various assays were: IL-1/?, 20pgmL"i; IL-1RA, 
800 pg mL™'1; TNF, 20 pg mL"1; sTNF-R:p55, 
80pgmL~\ p75, 300pgmL""1; and IL-6, 20UmL~1. 
Since sTNF-R levels are reported to correlate with 
serum creatinine levels and with the glomerular filtra­
tion rate, a corrected value for sTNF-R concentration 
was calculated as follows [22]:
Actual sTNF concentration x creatinine clearance
x 1/100
Statistical analysis
Values are reported as medians and range. Differences 
between medians were analysed using the Wilcoxon 
signed-rank test for paired and unpaired samples. 
P < 0*05 was considered significant. One-way analysis 
of variance ( a n o v a ) was used to assess differences in 
the observed cytokine patterns between patients with 
and patients without concomitant infections.
Results
Clinical characteristics o f patients and control 
subjects
All 10 patients (median age 45 years; range 29-69, 
four males, six females) had fever, dry cough and/or 
dyspnoea. Nine patients had interstitial or alveolar 
infiltrates on the chest radiograph; in one patient 
(number 4) the chest radiograph was normal.
Of the 10 patients, eight were renal transplant 
recipients with a median interval between transplanta­
tion and PCP of 3 months (range 2-30). One patient
©  1996 Blackwell Science Ltd, European Journal o f  Clinical Investigation* 26, 159-166
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Figure 2. Unslimulated and LPS-stimulated ex-vivo production of cytokincs, (IL-6 and TNF; IL-1 and IL-1RA) by alveolar cells and in whole- 
blood cultures from volunteers and HIV-seronegative patients with PCP in the acute phase and at recovery -, Median; • ,  patients without 
concom itant infections; O, patients with concomitant infections.
developed PCP while using prednisone for an un­
determined auto-immune disease, and one patient 
was treated with chemotherapy (including prednisone) 
for non-Hodgkin’s lymphoma. None of the patients 
used PCP chemoprophylaxis. The clinical and 
laboratory characteristics are summarized in 
Tables 1 and 2.
The median age of the eight healthy volunteers, two 
males and six females, was 24 (20-25) years.
Cytokines in BAL and blood
A measurable concentration of IL-6 (446 UmL“ 1) 
was present in BAL fluid from only 1 of the 10 PCP 
patients (Fig. la). The concentration of TNF in the 
BAL fluid was high (6-lngm L"1) in one patient 
(number 7), detectable (0, l~0*6ngmL~1) in five 
patients and bejow the detection limit in four patients.
interleukin- 10 concentrations were detectable in three 
patients (0* 16-0*24 ngmL"1) and below the detection 
limit in seven. The concentration of IL-RA in the 
BAL fluid from the PCP patients was 2*1 (0-4-9-9) 
ngmL"1 (Fig. la). In 4 of the 10 patients, the IL-IRA 
concentration in BAL fluid was above the upper normal 
limit of healthy volunteers (> 95% percentiles). Soluble 
TNF receptors could not be detected in BAL fluid, 
except in one patient (number 10), in whom values just 
above the detection limit were found (p55, 1 *2 ng mL'"1; 
p75, LSngmL"1). The IL-1RA concentration in BAL 
fluid from healthy volunteers was 0*75 (< 0’4-6’6) 
n g m L '1, which was significantly lower than in patients 
(P -  0-03, Fig. la). The concentrations of IL-6, TNF, 
IL-10  and sTNF-Rs in the BAL fluid from volunteers 
were below the detection limit.
In the patients, the plasma concentrations of the 
proinflammatory cytokines IL-6, TNF and IL-!/?
'O 1996 Blackwell Science Ltd, European Journal o f  Clinical Investigation, 26, 159-166
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Figure 2. Continued.
were low in the acute phase as well as at recovery (Fig. 
la). In contrast, the plasma concentration of the 
cytokine inhibitors were elevated in the acute phase. 
For IL-RA we found 2*4 (<0*8-10* 3) ngmL” 1, for 
sTNF-R-p55 10-8 (6*6— 17*7) ngm L "1 and for 
sTNF-R-p75 23 (14-36) ngm L "1 (Fig. lb). At
recovery, while using a low, maintenance dose (10- 
20 mg) of prednisone, the concentration of these 
inhibitors decreased in the patients but remained 
significantly higher than in healthy volunteers 
{P < 0*04). Even after correction for renal function, 
sTNF-R concentrations remained significantly 
higher than in healthy volunteers, both in the acute 
phase [p55, 3*5 (1-5—7-4) ngm L"1; p75, 9*1 (3*7-19*5) 
ngmL” 1] and during recovery [p55, 2*7 (0-8—8*7) 
ngmL"*1, p75, 3*9 (2-6-15*2) ngmL“1]. Corrected for 
renal function, p75 concentration was higher in the 
acute phase (P =  0*04) than during recovery, whereas 
for p55 concentration the difference between the acute
phase and the recovery period did not reach statistical 
difference.
Cytokine concentrations in blood and BAL were 
not correlated with severity of infection.
Ex vivo production of cytokines by alveolar cells and 
blood cells
In six patients (patients 1, 2, 5, 7, 8 and 10) adequate 
BAL material was obtained for assessment of ex vivo 
production by alveolar cells. The LPS-stimulated ex 
vivo production of the proinflammatory cytokines by 
the alveolar cells was suppressed in the acute phase of 
PCP (Fig. 2a and b). We also found a significant 
suppression of unstimulated and LPS-stimulated 
ex vivo production of IL-1RA by alveolar cells, 
compared with the production in healthy volunteers 
(P < 0*005, Fig. 2b). Bronchoalveolar lavage was 
not repeated during follcw-up.
© 1996 Blackwell Science Ltd, European Journal o f  Clinical Investigation* 26, 159-166
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The same pattern as with the alveolar cells was seen 
for the ex vivo production of the proinflammatory 
cytokines in the whole-blood cultures, i.e. suppression 
of the LPS-stimulated ex vivo production in the acute 
phase of PCP. At recovery the ex vivo production 
returned to the values of the volunteers. In contrast, 
the ex vivo production of IL-1 RA did not appear to be 
affected by disease. After correction for circulating 
concentrations present in the cultured blood, both 
unstimulated and LPS-stimulated IL-1RA production 
was virtually identical in the acute phase and at 
recovery and similar to the production in volunteers 
(Fig. 2b). The ex vivo production ofsTNF-R was not 
measured since previous experiments demonstrated 
that TN F receptors were hardly released during 
LPS-stimulation in the alveolar cell and whole-blood 
culture system (data not shown).
In two patients with PCP who were investigated 
recently, blood was drawn just before and 24 h after 
the start of high-dose (80 mg) prednisone; in both 
samples the proinflammatory cytokine production 
was strongly suppressed (24QpgmL"1 and 
260pgmL“ 1 for IL-1, SOOpgmL"1 and SSOpgmL” 1 
for TNF before the high-dose prednisone vs. 
lOOpgmL” 1 and 320pgmL"1 for IL-1, 220pgmL” 1 
and 320pgm L_1 for TNF after the high dose). 
Analysis of variance failed to detect differences in 
cytokine patterns between patients with and patients 
without concomitant infections (for all cytokines
P > 0-13).
Discussion
In this study, we followed, in 10 HIV-seronegative 
immunocompromised patients with PCP, circulating 
and ex vivo production of cytokines in whole-blood 
cultures during the course of infection and measured 
in the acute phase cytokine concentrations and ex vivo 
production at the site of infection (BAL fluid and 
alveolar cells).
Although in vitro and animal studies suggest an 
important role of the proinflammatory cytokines in 
the pathogenesis of PCP early in the course of the 
infection, we found low concentrations of these 
cytokines in the blood as well as at the site of 
infection (i.e. in the BAL fluid) [9-11]. One explanation 
could be that at first examination of the patient the 
infection has passed its initial acute stage, as most 
patients had symptoms for at least a couple of days.
We could not detect a relationship between body 
temperature and plasma concentrations of the pyro- 
genic cytokines TNF, IL-1/? and 11-6. Thus, it 
remains unclear how the febrile response during 
PCP is mediated. It is remarkable that even IL-6, a 
pyrogenic cytokine that reaches high circulating 
concentrations under many clinical conditions of 
systemic inflammation, was not detectable.
The high concentrations of the anti-inflammatory 
mediators IL-1 RA and sTNF-R-p75 (actual concen­
tration as well as the concentration corrected for
renal function) in the blood and IL-1RA in BAL 
fluid in the acute phase of the PCP suggest that 
counter-regulation of proinflammatory cytokines 
occurs in PCP. During convalescence, IL-1RA and 
sTNF-R-p75 decrease but remain above the levels seen 
in volunteers. What causes the high concentration of 
IL-1RA and p75 in these ‘healthy5 immunosuppressed 
patients needs further study. In our patients the LPS- 
stimulated ex vivo production of the proinflammatory 
cytokines in blood cells was suppressed in the acute 
phase and improved during convalescence, whereas the 
production capacity of the anti-inflammatory cytokine 
IL-1RA was preserved. Previously we have observed a 
similar pattern in patients with severe meningococcal 
infection and in patients with typhoid fever [23,24]. 
Other investigators also reported suppression of 
proinflammatory cytokine after endotoxin infusion 
and during other acute disease states [25,26].
We hypothesize that, during an acute infection, 
blood cells switch from a balanced proinflammatory 
and anti-inflammatory repertoire (such as seen in 
healthy volunteers) to an anti-inflammatory repertoire. 
During the recovery phase the cells gradually regain the 
balanced status.
The down-regulation of proinflammatory cytokine 
production of cells in the circulation would not 
necessarily imply a similar down-regulation at the 
level of the tissues and at the site of infection. 
However, in this study we found such down-regulation 
of proinflammatory cytokines also at the level of the 
alveolar macrophages, suggesting a more generalized 
phenomenon.
An intriguing finding is the disparity found between 
IL-1RA production by blood cells and alveolar cells. 
In volunteers, unstimulated alveolar cells readily 
produced IL-1RA, whereas unstimulated blood 
cells did not produce detectable amounts of this 
cytokine inhibitor. These findings are in agreement 
with observations of Kline et aL [27] and Moore et ai 
[28] who found that alveolar macrophages express 
steady-state levels of IL-1 RA mRNA under unstimu­
lated culture conditions, whereas peripheral blood 
cells do so only in response to LPS or adherent IgG. 
In addition, we found differential regulation of IL- 
1RA between blood an alveolar cells in the acute 
phase of PCP: here IL-1RA ex vivo production 
could be stimulated in the blood, but not in alveolar 
cells. Whether this down-regulation of the anti-inflam­
matory response has consequences, e.g. in terms of 
pulmonary damage, needs further study.
It is of interest that, despite the low TNF production 
capacity of the alveolar cells, TNF is present in the BAL 
fluid of 60% of the patients with PCP. The cellular 
source of this TNF is currently unclear, but it is unlikely 
to be derived from alveolar macrophages, since these 
cells are refractory in terms of TNF production. What 
accounts for the down-regulation of proinflammatory 
cytokine production with relatively preserved IL-1RA 
production in the course of an infection needs further 
research. Interleukin-4, a T-lymphocyte-derived
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cytokine known to block the production of IL-1, IL- 
6 and TNF by monocytes, is a potent stimulus for 
IL-1RA production [29,30]. It could therefore be 
involved in the switch. Likewise, the cytokines IL-10 
or TGF-/J could be involved [31,32].
An important question is what role immuno­
suppression and the concomitant infections play in 
our study. Several investigators indicate that gluco- 
corticosteriods and cyclosporin A decrease proinflam­
matory cytokine production [33-35]. With regard to 
IL-1RA production, Santos et al. [36] have reported a 
minimal influence of hydrocortisone on endotoxin- 
stimulated IL-1RA production in volunteers. In our 
study however, the pattern of cytokine production did 
not appear to be influenced by prednisone dose 
(ranging from 0 to 80 mg in the acute phase and 
from 0 to 20 mg in convalescence) and cyclosporin 
A treatment. The concomitant infections occuring in 
our patients did seem to influence cytokine patterns 
in the same direction as PCP, since the cytokine 
patters of the six patients without concomitant 
infections were not different from the others. 
Although it is reasonable to presume that the immuno­
suppressive drugs and the concomitant infections in 
these patients interfered with the magnitude of the 
cytokine production, the observed cytokine patterns 
do not seem to be greatly influenced by either these 
drugs or the concomitant infections.
In conclusion, we found elevated TNF concentra­
tions in BAL in acute PCP and elevated plasma levels 
of the anti-inflammatory cytokine IL-1RA and the 
soluble TNF receptors in the acute phase of a PCP in 
10 HI V-ser onega tive patients, with at the same time a 
suppressed production of proinflammatory cytokines, 
in the blood as well as at the site of infection. During 
convalescence the blood cells return to a balanced 
proinflammatory status. IL-1RA production in acute 
PCP was down-regulated in alveolar cells and pre­
served in blood cells.
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